<DOC>
	<DOCNO>NCT01430546</DOCNO>
	<brief_summary>The purpose study quantify burden treatment relapse refractory multiple myeloma patient receive lenalidomide one prior treatment myeloma .</brief_summary>
	<brief_title>Non-interventional Study Time Response Quality Life Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide Second Line</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<criteria>1 . Be least 18 year age 2 . Have confirm diagnosis MM 3 . Starting lenalidomide treatment MM ( due relapse refractory disease ) one prior treatment . 4 . Have personally sign date legally effective write informed consent form prior admission study . 5 . Must willing able understand comply study requirement . 1 . Individuals take experimental drug participate clinical trial within 30 day prior screen . 2 . Individuals significant psychiatric illness clinically significant acute/chronic uncontrolled medical condition might affect experience myeloma symptom ability describe .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Relapsed Refractory Multiple Myeloma</keyword>
</DOC>